1987
DOI: 10.1248/bpb1978.10.730
|View full text |Cite
|
Sign up to set email alerts
|

Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
102
0

Year Published

1989
1989
2016
2016

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 172 publications
(103 citation statements)
references
References 28 publications
1
102
0
Order By: Relevance
“…The archetypical member of this family, prolyl oligopeptidase (POP; EC 3.4.21.26), exclusively hydrolyzes peptide bonds C terminal to proline residues in peptides (31). It has been implicated in the pathophysiology of depression (20) and has attracted pharmaceutical attention, since POP inhibitors have shown potential in the treatment of amnesia (39) and Alzheimer's disease (36). Prolyl oligopeptidase has also served as a model for structural studies of serine oligopeptidases.…”
mentioning
confidence: 99%
“…The archetypical member of this family, prolyl oligopeptidase (POP; EC 3.4.21.26), exclusively hydrolyzes peptide bonds C terminal to proline residues in peptides (31). It has been implicated in the pathophysiology of depression (20) and has attracted pharmaceutical attention, since POP inhibitors have shown potential in the treatment of amnesia (39) and Alzheimer's disease (36). Prolyl oligopeptidase has also served as a model for structural studies of serine oligopeptidases.…”
mentioning
confidence: 99%
“…(2)(3)(4)(5), al though its physiological role still remains obscure. Since vasopressin, among these peptides, has been suggested to be deeply involved in the process of learning and memory in animal experiments (6-9), Yoshimoto et al synthesized a variety of PED inhibitors and demon strated a probable relationship between their PED in hibition in vitro and anti-amnesic activity in vivo (10). In addition, a significant elevation of PED activity has recently been observed in the brain of patients with Alzheimer's disease (11).…”
mentioning
confidence: 99%
“…PREP is widely distributed in the brain (Irazusta et al, 2002;Myöhänen et al, 2007Myöhänen et al, , 2008 and increased activity of PREP has been associated with cell death processes in various neurodegenerative diseases, including Alzheimer's and Parkinson's diseases (Brandt et al, 2008;Mantle et al, 1996). PREP is believed to act in the extracellular space with involvement in the maturation and degradation of peptide hormones and neuropeptides (Bellemere et al, 2004;Cunningham and O'Connor, 1997;Shishido et al, 1999), which has been proposed to be the mechanism underlying some beneficial effects of PREP inhibitors in animal memory models (Shishido et al, 1998;Toide et al, 1997;Yoshimoto et al, 1987) and in aged mice (Kato et al, 1997). Besides its extracellular action, PREP has been shown to act intracellularly and important roles of PREP have been demonstrated in signaling pathways or in transport and secretion of proteins and peptides associated with neurodegeneration (Brandt et al, 2008;Di Daniel et al, 2009;Rossner et al, 2005;Savolainen et al, 2015;Schulz et al, 2002Schulz et al, , 2005.…”
Section: Introductionmentioning
confidence: 99%